Sign up to save your podcasts
Or
Share No pain, no gain: Ozempic’s quest for market share
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
No pain, no gain: Ozempic’s quest for market share
The shock success of GLP-1 treatments for obesity carries massive implications for wealthy societies and manufacturers Novo Nordisk and Eli Lilly alike. In this week’s Viewsroom podcast, Breakingviews columnists discuss how this would-be jackpot has companies running to keep up.
Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By Reuters
4.2
4545 ratings
The shock success of GLP-1 treatments for obesity carries massive implications for wealthy societies and manufacturers Novo Nordisk and Eli Lilly alike. In this week’s Viewsroom podcast, Breakingviews columnists discuss how this would-be jackpot has companies running to keep up.
Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising.
Learn more about your ad choices. Visit megaphone.fm/adchoices
More shows like Viewsroom
View all
NPR News Now
14,381 Listeners
Marketplace Morning Report
924 Listeners
WSJ Your Money Briefing
1,721 Listeners
Bloomberg Intelligence
408 Listeners
Bloomberg Businessweek
431 Listeners
Trumponomics
355 Listeners
WSJ Tech News Briefing
1,637 Listeners
The Big View
28 Listeners
Up First from NPR
56,472 Listeners
Bold Names
1,451 Listeners
Consider This from NPR
6,389 Listeners
The Big Take
157 Listeners
Reuters World News
271 Listeners
WSJ's Take On the Week
146 Listeners
Reuters Econ World
27 Listeners